SiBone (NASDAQ:SIBN) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen downgraded shares of SiBone (NASDAQ:SIBN) from a buy rating to a hold rating in a research note released on Saturday morning.

A number of other equities analysts also recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of SiBone in a research report on Monday, December 29th. Truist Financial lowered their price target on SiBone from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, TD Cowen upped their target price on SiBone from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

SiBone Price Performance

Shares of NASDAQ SIBN opened at $14.09 on Friday. The business’s 50 day moving average price is $14.09 and its two-hundred day moving average price is $16.33. The company has a market cap of $622.36 million, a PE ratio of -32.02 and a beta of 0.77. The company has a quick ratio of 7.21, a current ratio of 8.55 and a debt-to-equity ratio of 0.20. SiBone has a twelve month low of $12.15 and a twelve month high of $21.89.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.09. The firm had revenue of $56.35 million for the quarter, compared to the consensus estimate of $56.26 million. SiBone had a negative return on equity of 11.01% and a negative net margin of 9.41%. On average, analysts predict that SiBone will post -0.78 EPS for the current year.

Insider Buying and Selling

In other news, CEO Laura Francis sold 93,475 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $15.32, for a total value of $1,432,037.00. Following the transaction, the chief executive officer owned 544,369 shares of the company’s stock, valued at approximately $8,339,733.08. This represents a 14.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Anthony J. Recupero sold 21,049 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $15.40, for a total value of $324,154.60. Following the completion of the transaction, the insider directly owned 243,418 shares in the company, valued at $3,748,637.20. The trade was a 7.96% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 167,697 shares of company stock valued at $2,551,086 in the last ninety days. 4.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On SiBone

A number of large investors have recently added to or reduced their stakes in the stock. Diversified Trust Co grew its position in SiBone by 10.8% during the first quarter. Diversified Trust Co now owns 24,335 shares of the company’s stock worth $307,000 after buying an additional 2,375 shares in the last quarter. Invesco Ltd. grew its position in SiBone by 18.5% during the fourth quarter. Invesco Ltd. now owns 55,715 shares of the company’s stock worth $1,099,000 after buying an additional 8,706 shares in the last quarter. Susquehanna Portfolio Strategies LLC grew its position in SiBone by 579.2% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 105,365 shares of the company’s stock worth $2,078,000 after buying an additional 89,851 shares in the last quarter. Tudor Investment Corp ET AL grew its position in SiBone by 0.6% during the fourth quarter. Tudor Investment Corp ET AL now owns 259,589 shares of the company’s stock worth $5,119,000 after buying an additional 1,557 shares in the last quarter. Finally, Man Group plc acquired a new stake in SiBone during the fourth quarter worth approximately $965,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.